Helen H. Moon, MD, discusses the results of the TIVO-3 trial of tivozanib for patients with recurrent clear cell renal cell carcinoma.
Helen H. Moon, MD, principal investigator with the Cancer Clinical Trials Access Program in the Southern California Permanente Medical Group, research lead for melanoma, regional medical oncology lead for genitourinary cancer, and hematologist/oncologist at Kaiser Permanante Riverside Medical Center, discusses the results of the TIVO-3 trial (NCT02627963) of tivozanib (Fotivda) for patients with recurrent clear cell renal cell carcinoma (ccRCC).
The phase 3 TIVO-3 trial randomly assigned patients with ccRCC who had failed 2 or 3 prior systemic regimens 1:1 to receive tivozanib or sorafenib (Nexavar). The primary end point was progression-free survival (PFS). The trial met this end point with a hazard ratio of 0.73 favoring tivozanib for PFS, with a median PFS of 5.6 months versus 3.9 months with sorafenib (95% CI, 0.56-0.94; P = .016). The objective response rate (ORR) was 18% for tivozanib versus 8% with sorafenib at the primary analysis.
In terms of tolerability, patients who were heavily pretreated showed no unexpected adverse events (AEs). The most common AE was hypertension, which Moon says is a class effect of tyrosine kinase inhibitors (TKIs) and is thought to be on-target, indicating that this is a potent TKI.
TRANSCRIPTION:
0:08 | TIVO-3 is a positive study against an active comparator; in this case, it's sorafenib. So about 350 patients were randomized in 1:1 fashion. And the primary end point, which is PFS, was met. The hazard ratio was 0.73, with a significant confidence interval and ORR about [18%], which is nearly a doubling of the response rate for sorafenib.
What it showed is that even in this heavily pretreated group of patients—most of them are third line, some of them are fourth-line therapy—that they held up relatively well, with no unexpected serious AE. The most commonly seen AE is hypertension, which we believe is on-target hit of this class of medication and demonstrating tivozanib is likely a very potent TKI.
Patient Preference Plays Limited Role in Selection of Therapy for Melanoma
May 17th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants whether factors such as patient preference influence their choice of melanoma treatment in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Discussing Non-Clinical Barriers to NGS Testing for NSCLC
May 15th 2024During a Case-Based Roundtable® event, Julia Rotow, MD, led a discussion on the non-clinical barriers that impact the use of using next-generation sequencing for patients with certain mutations of their non–small cell lung cancer in the first article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Lower-Dose Selinexor Data Lead to Patient Selection Questions in RRMM
May 14th 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Read More
Experience and Sequencing Guide Third-Line DLBCL Therapy Selection
May 13th 2024During a Case-Based Roundtable® event, Matthew Ulrickson, MD, discussed experiences with loncastuximab and other targeted treatments in patients with diffuse large B-cell lymphoma with event participants in the first article of a 2-part series.
Read More